The findings revealed that the risk score was better than tumour type (primary and recurrent), tumour grade, sex, age, LGG diagnosis type, PTEN mutation status, IDH1 R132 mutation status, EGFR mutation status, ATRX mutation status and TP53 mutation status (Figures 5G–I). This evidence concerns the gene ATRX and neoplasm.